These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22571484)

  • 41. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.
    Nakamura K; Ariyoshi N; Iwatsubo T; Fukunaga Y; Higuchi S; Itoh K; Shimada N; Nagashima K; Yokoi T; Yamamoto K; Horiuchi R; Kamataki T
    Biol Pharm Bull; 2005 May; 28(5):882-5. PubMed ID: 15863898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.
    Hamitouche S; Poupon J; Dreano Y; Amet Y; Lucas D
    Toxicol Lett; 2006 Dec; 167(3):221-30. PubMed ID: 17084997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19.
    Zhang W; Ramamoorthy Y; Tyndale RF; Glick SD; Maisonneuve IM; Kuehne ME; Sellers EM
    Drug Metab Dispos; 2002 Jun; 30(6):663-9. PubMed ID: 12019193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
    Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates.
    Graham MJ; Bell AR; Crewe HK; Moorcraft CL; Walker L; Whittaker EF; Lennard MS
    Xenobiotica; 2003 Mar; 33(3):225-37. PubMed ID: 12637241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.
    Foti RS; Dickmann LJ; Davis JA; Greene RJ; Hill JJ; Howard ML; Pearson JT; Rock DA; Tay JC; Wahlstrom JL; Slatter JG
    Xenobiotica; 2008 Mar; 38(3):264-80. PubMed ID: 18274956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.
    Desta Z; Soukhova NV; Flockhart DA
    Antimicrob Agents Chemother; 2001 Feb; 45(2):382-92. PubMed ID: 11158730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
    Galetin A; Houston JB
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
    Isvoran A; Louet M; Vladoiu DL; Craciun D; Loriot MA; Villoutreix BO; Miteva MA
    Drug Discov Today; 2017 Feb; 22(2):366-376. PubMed ID: 27693711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
    Chang SY; Chen C; Yang Z; Rodrigues AD
    Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
    Hasegawa M; Tahara H; Inoue R; Kakuni M; Tateno C; Ushiki J
    Drug Metab Dispos; 2012 Mar; 40(3):474-80. PubMed ID: 22126990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
    Houston JB; Kenworthy KE
    Drug Metab Dispos; 2000 Mar; 28(3):246-54. PubMed ID: 10681367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
    Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The transcriptional regulation of the human CYP2C genes.
    Chen Y; Goldstein JA
    Curr Drug Metab; 2009 Jul; 10(6):567-78. PubMed ID: 19702536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enzyme source effects on CYP2C9 kinetics and inhibition.
    Kumar V; Rock DA; Warren CJ; Tracy TS; Wahlstrom JL
    Drug Metab Dispos; 2006 Nov; 34(11):1903-8. PubMed ID: 16928789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes.
    Ono S; Hatanaka T; Hotta H; Satoh T; Gonzalez FJ; Tsutsui M
    Xenobiotica; 1996 Jul; 26(7):681-93. PubMed ID: 8819299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation.
    Schmider J; Greenblatt DJ; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1996 Jun; 41(6):593-604. PubMed ID: 8799527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism.
    Shou M; Lu T; Krausz KW; Sai Y; Yang T; Korzekwa KR; Gonzalez FJ; Gelboin HV
    Eur J Pharmacol; 2000 Apr; 394(2-3):199-209. PubMed ID: 10771285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.